Home/Pipeline/CD19 CAR-T

CD19 CAR-T

B-cell Lymphoma

ClinicalActive (Study Published)

Key Facts

Indication
B-cell Lymphoma
Phase
Clinical
Status
Active (Study Published)
Company

About BinDeBio

Chinese biotech group developing next-generation CAR-T and TCR-T cell therapies for cancer treatment.

View full company profile

Therapeutic Areas

Other B-cell Lymphoma Drugs

DrugCompanyPhase
CAR-T Response ModelQuibimResearch
VNX-103Vironexis BiotherapeuticsIND-Enabling
ELC-301Elicera TherapeuticsPhase I/II